Patents by Inventor Renaud Grepin

Renaud Grepin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230192833
    Abstract: The invention relates to an isolated anti-vascular endothelial growth factor-C (VEGFC) antibody or a functional fragment thereof, said antibody comprising a heavy chain comprising at least one, preferentially at least two, preferentially three, of CDR-H1, CDR-H2 and CDR-H3 of amino acid sequences SEQ ID N° 6, 7 and 8 and a light chain comprising at least one, preferentially at least two, preferentially three of CDR-L1, CDR-L2 and CDR-L3 of amino acid sequences SEQ ID N° 9, 10 and 11, respectively.
    Type: Application
    Filed: March 19, 2021
    Publication date: June 22, 2023
    Inventors: Gilles PAGES, Renaud GREPIN, Aurore DUMOND
  • Patent number: 10047156
    Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 14, 2018
    Assignees: Centre National De La Recherche Scientifique (CNRS), Universite de Nice Sophia Antipolis
    Inventors: Gilles Pages, Renaud Grepin
  • Publication number: 20160108117
    Abstract: The invention provides an isolated antibody or a fragment thereof, which is directed to the human chemokines CXCL1, CXCL7 and CXCL8, said antibody or fragment being capable of binding to the human chemokine CXCL1 with an equilibrium dissociation constant (KD) of at most 16 nM, to the human chemokine CXCL7 with an equilibrium dissociation constant (KD) of at most 5 nM and to the human chemokine CXCL8 with an equilibrium dissociation constant (KD) of at most 45 nM, as determined by surface plasmon resonance. The invention also provides some applications of said isolated antibody.
    Type: Application
    Filed: May 19, 2014
    Publication date: April 21, 2016
    Applicants: UNIVERSITE DE NICE SOPHIA ANTIPOLIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gilles Pages, Renaud Grepin